A 36-Week Safety Extension Study of ELND005 as a Treatment for Agitation and Aggression in Alzheimer's Disease
Status:
Terminated
Trial end date:
2015-08-01
Target enrollment:
Participant gender:
Summary
To evaluate the safety and tolerability of ELND005 treatment with up to 36 weeks exposure, in
Moderate to Severe AD patients with agitation and aggression.
Phase:
Phase 2
Details
Lead Sponsor:
OPKO Health, Inc. Transition Therapeutics Ireland Limited